| Literature DB >> 30546950 |
Hans A Schlößer1,2, Martin Thelen2, Axel Lechner2,3, Kerstin Wennhold2, Maria A Garcia-Marquez2, Sacha I Rothschild4, Elena Staib2, Thomas Zander5, Dirk Beutner3, Birgit Gathof6, Ramona Gilles6, Engin Cukuroglu7, Jonathan Göke7, Alexander Shimabukuro-Vornhagen5, Uta Drebber8, Alexander Quaas8, Christiane J Bruns1, Arnulf H Hölscher1, Michael S Von Bergwelt-Baildon9,10.
Abstract
Tumor-infiltrating lymphocytes (TILs) are correlated to prognosis of several kinds of cancer. Most studies focused on T cells, while the role of tumor-associated B cells (TABs) has only recently gained more attention. TABs contain subpopulations with distinct functions, potentially promoting or inhibiting immune responses. This study provides a detailed analysis of TABs in gastro-esophageal adenocarcinoma (EAC). Flow cytometric analyses of single cell suspensions of tumor samples, mucosa, lymph nodes and peripheral blood mononuclear cells (PBMC) of EAC patients and healthy controls revealed a distinct B cell compartment in cancer patients. B cells were increased in tumor samples and subset-analyses of TILs showed increased proportions of differentiated and activated B cells and an enrichment for follicular T helper cells. Confocal microscopy demonstrated that TABs were mainly organized in tertiary lymphoid structures (TLS), which resemble lymphoid follicles in secondary lymphoid organs. A panel of 34 tumor-associated antigens (TAAs) expressed in EAC was identified based on public databases and TCGA data to analyze tumor-specific B cell responses using a LUMINEXTM bead assay and flow cytometry. Structural analyses of TLS and the detection of tumor-specific antibodies against one or more TAAs in 48.1% of analyzed serum samples underline presence of anti-tumor B cell responses in EAC. Interestingly, B cells were decreased in tumors with expression of Programmed Death Ligand 1 or impaired HLA-I expression. These data demonstrate that anti-tumor B cell responses are an additional and underestimated aspect of EAC. Our results are of immediate translational relevance to emerging immunotherapies.Entities:
Keywords: Plasma cells; antibody; esophageal cancer; tumor associated antigen
Year: 2018 PMID: 30546950 PMCID: PMC6287776 DOI: 10.1080/2162402X.2018.1512458
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110